This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rogers, W. J. Search for Related Content PubMed PubMed Citation Articles by Rogers, W. J.

CLINICAL STUDY: MYOCARDIAL INFARCTION

Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999

The National Registry of Myocardial Infarction 1, 2 and 3

William J. Rogers, MD, FACC^*, John G. Canto, MD, MSPH, FACC^*, Costas T. Lambrew, MD, FACC, Alan J. Tiefenbrunn, MD, FACC, Becky Kinkaid, David A. Shoultz, PhD^||, Paul D. Frederick, MPH, MBA^||, Nathan Every, MD, MPH, FACC^|| for the Investigators in the National Registry of Myocardial Infarction 1 2 and 3^¶

^* University of Alabama Medical Center, Birmingham, Alabama, USA
Maine Medical Center, Portland, Maine, USA
Washington University School of Medicine, St. Louis, Missouri, USA
Genentech, Inc., South San Francisco, California, USA
^|| University of Washington, Seattle, Washington, USA

Manuscript received November 2, 1999; revised manuscript received May 31, 2000, accepted July 14, 2000.

Reprint requests and correspondence: Dr. William J. Rogers, 334 LHRB, University of Alabama Medical Center, Birmingham, Alabama 35294
wrogers{at}uab.edu

	Abstract

Top Abstract Methods Results Discussion References

 
OBJECTIVES

We sought to determine trends in the treatment of myocardial infarction from 1990 through 1999 in the U.S. and to relate these trends to current guidelines.

BACKGROUND

Limited data are available to show how recent clinical trials and clinical guidelines have impacted treatment of myocardial infarction.

METHODS

Temporal trends in myocardial infarction treatment and outcome were assessed by using data from 1,514,292 patients in the National Registry of Myocardial Infarction (NRMI) 1, 2 and 3 from 1990 through 1999.

Results

During this interval, the use of intravenous thrombolytic therapy declined from 34.3% to 20.8%, but the use of primary angioplasty increased from 2.4% to 7.3% (both p = 0.0001). The median "door-to-drug" time among thrombolytic therapy recipients fell from 61.8 to 37.8 min (p = 0.0001), primarily owing to shorter "door-to-data" and "data-to-decision" times. The prevalence of non–Q wave infarctions increased from 45% in 1994 to 63% in 1999 (p = 0.0001). From 1994 through 1999, there was increased usage of beta-blockers, aspirin and angiotensin-converting inhibitors, both during the first 24 h after admission and on hospital discharge (all p = 0.0001). Between 1990 and 1999, the median duration of hospital stay fell from 8.3 to 4.3 days, and hospital mortality declined from 11.2% to 9.4% (both p = 0.0001).

CONCLUSIONS

The NRMI data from 1990 through 1999 demonstrate that the recommendations of recent clinical trials and published guidelines are being implemented, resulting in more rapid administration of intravenous thrombolytic therapy, increasing use of primary angioplasty and more frequent use of adjunctive therapies known to reduce mortality, and may be contributing to the higher prevalence of non–Q wave infarctions, shorter hospital stays and lower hospital mortality.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   AMI = acute myocardial infarction   CABG = coronary artery bypass graft surgery   ECG = electrocardiogram or electrocardiographic   LBBB = left bundle branch block   IV = intravenous   NRMI = National Registry of Myocardial Infarction   PTCA = percutaneous transluminal coronary angioplasty   rt-PA = recombinant tissue-type plasminogen activator

In July 1990, the National Registry of Myocardial Infarction (NRMI) was initiated to provide participating hospitals a means of tracking the characteristics, treatment and outcome of their patients with AMI. The composite data from the 1,514,292 patients entered from 1990 through 1999 in the first three phases of NRMI (NRMI 1, 2 and 3) should provide insight into the evolving national practice patterns for treatment of AMI. This report describes trends in the presenting characteristics, treatment and outcome of patients with AMI from 1990 through 1999, as reflected by this large U.S. registry, and relates these trends to the recommendations of recent clinical trials and to heath care reform.

	Methods

Top Abstract Methods Results Discussion References

 
Data collection.   The NRMI is an industry-sponsored, prospective, observational study (3). On entering NRMI, hospitals were asked to complete a form characterizing their facilities and services and then to record data from consecutive patients with AMI onto two-page case report forms, which were forwarded to an independent statistical center. Case report forms were less detailed for NRMI 1 (1990–1994) than for NRMI 2 (1994–1998) or NRMI 3 (1998 to present). Hospitals received quarterly reports summarizing local registry data, as well as parallel data from the state, nation and hospitals of similar bed size and invasive cardiovascular capability. To ensure quality control of registry data, registry coordinators were trained in data entry, utilizing a standardized manual of instructions and definitions. Case report forms were required to pass systematic range and internal consistency checking. Hospitals obtained approval of the registry data collection process as dictated by local policy.

Trend analysis.   Data were grouped according to the calendar year of each patient’s hospital arrival. Phase 1 of NRMI began in July 1990, so the initial period of data collection was six months in duration. For data variables common among NRMI 1, 2 and 3, trends over the period 1990–1999 were assessed. For variables contained only in the more detailed NRMI 2 and 3 data bases, trend analyses were confined to the period 1994–1999.

Definitions.   Myocardial infarction was defined by local hospital criteria, usually including a history suggestive of AMI accompanied by either total creatine kinase or creatine kinase, MB fraction greater than or equal to twice the upper limit of normal for the hospital’s laboratory, or electrocardiographic (ECG) evidence of AMI, or, in the absence of these, alternative enzymatic, scintigraphic, echocardiographic or autopsy evidence of AMI—culminating in an International Classification of Diseases (9th revision, clinical modification) discharge diagnosis code of 410.01 through 410.91 for AMI.

Hospitals were considered urban if located in a county with at least one city having a population >50,000 or two cities having a combined population >50,000. Treatment intervals for administration of thrombolytic therapy were defined according to the National Heart Attack Alert Program, where "door" indicates the time of patient presentation to the hospital; "data" represents the time of acquisition of the diagnostic ECG; "decision" means the time it was decided to administer thrombolytic therapy; and "drug" indicates the time thrombolytic therapy was initiated (4). Major bleeding included hemorrhagic episodes, other than intracranial bleeding, resulting in substantial hemodynamic compromise. Because many hospitals "dropped out" and "dropped into" the registry over time, "core hospitals" were identified; they contributed at least six patients during each six-month interval throughout NRMI 2 and 3 or the combined NRMI 1, 2 and 3 intervals. Core hospitals were identified separately for the NRMI 2 and 3 trend analysis and for the combined NRMI 1, 2, and 3 analyses.

Statistical analysis.   For categoric data, the Mantel-Haenszel chi-square test was used as the measure of trend. For continuous data, one-way analysis of variance was used to test the null hypothesis that multiple population mean values are all equal. To test median values across multiple groups, p values were computed using the nonparametric Brown-Mood test. All statistical analyses were performed using a commercially available statistical package (SAS 6.12 [1996], SAS Institute, Cary, North Carolina). This report is based on data processed by the statistical center as of April 25, 2000.

	Results

Top Abstract Methods Results Discussion References

 
Characteristics of participating hospitals (Table 1).   A total of 1,249 hospitals contributed patients to NRMI 1; 1,843 hospitals to NRMI 2 and 3; and 2,033 hospitals to NRMI 1, 2 and 3. However, the number of hospitals participating in the registry at any point in time was variable and ranged from 352 to 1,460. There were 58 "core" hospitals for the combined NRMI 1, 2 and 3 experience, and there were 572 core hospitals for the combined NRMI 2 and 3 experience. The average registry hospital had 250 to 300 beds and was nonteaching and urban and had capabilities for coronary arteriography, but less often percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG).

View larger version (28K): [in this window] [in a new window]   Figure 1 Use of reperfusion therapy in all patients and in those presenting with ST segment elevation or LBBB within 12 h of symptom onset. A, A total of 1,514,292 patients were enrolled in NRMI 1, 2 and 3. B, A total of 376,753 patients in NRMI 2 and 3 presented with ST segment elevation or LBBB within 12 h of symptom onset. Either = either IV lytic or primary PTCA; IV lytic = intravenous thrombolytic therapy.

Among patients in NRMI 2 and 3 presenting with ST segment elevation or LBBB within 12 h of symptom onset, the proportion receiving immediate IV thrombolytic therapy or primary PTCA increased only slightly (from 68.8% to 70.0%, p = 0.0014), as the rise in the use of primary PTCA exceeded the fall in the use of IV thrombolytic therapy (Fig. 1B). Among patients treated in NRMI 2 and3 hospitals having the capability for both PTCA and CABG, the use of IV thrombolytic therapy fell from 59.1% in 1994 to 47.9% in 1999, whereas the use of primary PTCA increased from 11.8% to 24.4% (both p = 0.0001).

Time to treatment.   Among the 1,514,292 patients enrolled in NRMI 1, 2 and 3, the interval from symptom onset to hospital arrival fell only marginally between 1990 and 1999 (from a median of 2.2 to 2.0 h, p = 0.0001). Door-to-drug time was recorded only for recombinant tissue-type plasminogen activator (rt-PA) in NRMI 1. Among the 295,056 patients treated with rt-PA in NRMI 1, 2 and 3, the median interval from hospital arrival to initiating rt-PA (door-to-drug time) shortened significantly (Fig. 2A) (from 61.8 to 37.8 min, p = 0.0001). In NRMI 2 and 3, the door-to-drug time, as well as its component time intervals, was assessed for recipients of all IV thrombolytic agents. Among 266,177 such patients, the median door-to-drug time fell from 47 min in 1994 to 38 min in 1999, primarily due to shortening of the door-to-data interval (from 15.0 to 10.8 min) and a reduction in the data-to-decision interval (from 19.2 to 15.0 min, all p = 0.0001) (Fig. 2B).

View larger version (27K): [in this window] [in a new window]   Figure 2 Door-to-drug intervals. A, Door-to-drug interval in 295,056 patients treated with rt-PA. Although the time to treatment shortened significantly, it did not achieve the goal of 30 min. B, Door-to-drug subintervals in 266,177 patients treated with all IV thrombolytic agents.

Medication use in first 24 h (Fig. 3).   During the first 24 h after presentation, the 1,161,550 patients in NRMI 2 and 3 showed upward trends in the use of aspirin, IV beta-blockers, oral beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, antiplatelet therapy other than aspirin (all p = 0.0001) and antithrombin therapy other than heparin (p = 0.0018). Also noted was less use of calcium channel blockers, IV lidocaine, IV nitroglycerin and unfractionated heparin (all p = 0.0001). Among the 298,486 recipients of IV thrombolytic therapy in NRMI 2 and 3, similar upward trends were noted for aspirin (from 88.6% to 93.5%), IV beta-blockers (from 24.3% to 36.6%), oral beta-blockers (from 35.5% to 49.6%), either IV or oral beta-blockers (from 48.4 to 66.9%) and ACE inhibitors (from 7.5% to 18.9%) (all p = 0.0001).

View larger version (34K): [in this window] [in a new window]   Figure 3 Medication (Meds) usage during first 24 h after hospital admission among 1,161,550 patients in NRMI 2 and 3. Ca blocker = calcium channel blocker; TNG = nitroglycerin.

Hospital outcome.   Among the 1,161,550 patients in NRMI 1, 2 and 3, the duration of hospital stay declined sharply (from a median of 8.3 days in 1990 to 4.3 days in 1999, p = 0.0001) (Fig. 4). The fall in length of hospital stay among patients receiving primary PTCA or IV thrombolytic therapy was similar to that of all patients. During this same interval, hospital mortality fell (from 11.2% in 1990 to 9.4% in 1999, p = 0.0001) (Fig. 5). Hospital mortality also declined among patients receiving primary PTCA or IV thrombolytic therapy, but in the latter group, the decline was not quite as sharp as in the overall population. Among patients in NRMI 2 and 3 in whom the initial ECG findings were tabulated, similar mortality trends were noted between 1994 and 1999 for those presenting with findings of ST segment elevation or LBBB (n = 533,452) or for those presenting without such findings (n = 628,098) (10.6% to 9.8% and 9.9% to 9.1%, respectively, both p = 0.0001).

View larger version (20K): [in this window] [in a new window]   Figure 4 Length of hospital stay among 1,514,292 patients in NRMI 1, 2 and 3. The length of stay shortened among all patients and in those receiving IV thrombolytic therapy or primary PTCA. IV lytic = intravenous thrombolytic therapy.

View larger version (19K): [in this window] [in a new window]   Figure 5 Hospital mortality among 1,514,292 patients in NRMI 1, 2 and 3. Hospital mortality declined among all patients and in those receiving IV thrombolytic therapy and primary PTCA. IV lytic = intravenous thrombolytic therapy.

Among the 1,161,550 patients in NRMI 2 and 3, a reduction was noted for cardiogenic shock (from 5.6% to 4.5%), sustained ventricular tachycardia or fibrillation (from 7.8% to 6.4%), reinfarction (from 3.3% to 1.8%), total stroke (from 1.5% to 1.1%) and cardiac rupture or electromechanical dissociation (from 0.9% to 0.6%). Major bleeding increased slightly (from 2.6% to 2.7%) (all p = 0.0001).

Discharge medications (Fig. 6).   Among the 805,341 patients in NRMI 2 and 3 who were discharged alive and not transferred out of the registry hospitals, upward trends were noted between 1994 and 1999 for discharge prescription of aspirin, beta-blockers, ACE inhibitors, antiarrhythmic agents and diuretic agents. Downward trends were observed for prescription of nitrates, calcium channel blockers and digoxin (all p = 0.0001). Usage of lipid-lowering therapy, recorded only in NRMI 3, increased from 29.2% in 1998 to 36.2% in 1999 (p = 0.0001).

View larger version (28K): [in this window] [in a new window]   Figure 6 Medications prescribed at hospital discharge. The most notable upward trends were in medications shown to improve survival, such as aspirin, beta-blockers and ACE inhibitors. Ca blocker = calcium channel blocker.

	Discussion

Top Abstract Methods Results Discussion References

 
The NRMI is the largest data base of AMI in the world, currently enrolling patients from over one-fourth of all acute-care hospitals in the U.S. This report shows that, from 1990 through 1999, practice patterns evolved generally in accordance with recommendations of recent clinical trials and published guidelines and resulted in more rapid implementation of thrombolytic therapy and greater use of appropriate adjunctive therapy. In parallel with ongoing national health care reform, there was an increase in health maintenance organizations as the primary payer for infarct-related admissions and a sharp reduction in hospital stays. In accordance with physician preference, there was a steep increase in the use of primary PTCA and a decrease in the use of thrombolytic therapy. Finally, hospital mortality declined, both in patients receiving and in patients not receiving reperfusion interventions.

Changing patterns for utilization of reperfusion therapy.   Because reperfusion therapy lowers the mortality of AMI, it should be implemented in every eligible patient (5). Surprisingly, the proportion of patients receiving an early reperfusion intervention declined from 1990 through 1999 (Fig. 1A). In large part, this may have been due to a declining eligibility for reperfusion, rather than to an increasing failure to treat eligible patients. There was a fall in the proportion of patients presenting within 12 h with ST segment elevation or LBBB, the group known to benefit from thrombolytic therapy (6). The proportion of such subjects who were treated with either thrombolytic therapy or primary angioplasty remained relatively stable (Fig. 1B). However, as previously noted, over 25% of these patients did not have an early reperfusion intervention (7). The fact that the proportion of untreated eligible patients has remained stable since 1994, despite the growing utilization of primary PTCA, suggests that the latter intervention is being employed primarily in thrombolytic candidates, rather than as an "additional" means of reperfusing thrombolytic ineligible patients.

Factors determining time to treatment.   Because AMI is a time-dependent process, the speed of implementation of thrombolytic therapy is critical in limiting myocardial injury and mortality (5,8). From 1990 through 1999, the door-to-drug interval fell significantly in the NRMI population (Fig. 2A), but did not achieve the goal of 30 min, as proposed by the National Heart Attack Alert Program (4). As previously reported, the major component of delay is the data-to-decision time (Fig. 2B), the interval during which "consultation" as to whether thrombolytic therapy should be administered is often sought between emergency department personnel and another physician, such as the patient’s primary physician, an internist or a cardiologist (9). This consultative delay may increase both time to treatment and mortality (9).

To reduce the data-to-decision time, it has been recommended that hospitals empower emergency physicians to treat patients with typically presenting symptoms of AMI immediately, without consultation (4). This policy is being successfully implemented, at least in some NRMI hospitals, as evidenced by the decline in frequency of consultation before thrombolysis, the increasing proportion of emergency physicians as the ones ordering thrombolytic therapy and the fall in the data-to-decision interval from 1990 through 1999.

Relation of medication usage and procedures to evidence-based guidelines.   Multiple, randomized, controlled clinical trials over the past two decades have investigated the impact of adjunctive pharmacotherapies and mechanical interventions on survival after AMI. The NRMI data show that practitioners have begun to incorporate many of the findings of these trials into practice. Medications shown to improve early- and long-term survival, including aspirin (8,10), beta-blockers (11) and ACE inhibitors (12), have increased in usage during the first 24 h of the hospital period (Fig. 3) and at hospital discharge (Fig. 6), whereas the use of agents with potentially deleterious effects, such as calcium channel blockers (13) and lidocaine (14) has declined. The use of "other antiplatelet therapy" has increased in parallel with the increasing prevalence of early angioplasty. The use of most other agents has remained stable.

Despite the favorable trends in the utilization of pharmacologic therapy, there would appear to be potential for further improvement. Although NRMI did not assess eligibility for each of the adjunctive therapies, it is likely that, in recipients of thrombolytic therapy, the most recently cited rates of utilization were suboptimal for aspirin, beta-blockers and ACE inhibitors during the first 24 h (93.5%, 66.9% and 18.9%, respectively), especially because the rates of utilization for these agents was 97.4%, 80.8% and 53.9%, respectively, in the most recently reported large-scale clinical trial of thrombolytic therapy (15).

Routine coronary arteriography and mechanical revascularization after infarction have not been found to improve the rates of survival or subsequent AMI in most (6,16–18), but not all, studies (19). In NRMI, the use of coronary arteriography declined from 1990 through 1999, but the use of PTCA increased. The decline in coronary arteriography was likely an artifact due to the influx into the registry of hospitals without the capability for invasive procedures. Indeed, among the stable cohort of NRMI 1, 2 and 3 core hospitals, the use of both coronary arteriography and PTCA increased from 1990 through 1999. The relatively high use of postinfarction coronary arteriography in the U.S., as reflected by NRMI, represents a singular departure from otherwise close adherence to the majority of clinical trial recommendations.

Exercise testing four to six days after infarction, either before or just after discharge, has been recommended as appropriate clinical practice (2). However, NRMI data show that predischarge stress testing is declining and is currently performed in <10% of patients. Reasons for the decline likely include the fact that patients are often discharged before stress testing can be scheduled or safely undertaken, and because many patients undergo coronary arteriography and revascularization before discharge.

Changing outcomes for AMI: hospital stay, mortality and morbidity.   The most impressive trend in the current report is the dramatic decline in hospital stay (Fig. 4). The progressive decline in length of stay may be related to the increasing use of appropriate pharmacologic and mechanical interventions to limit infarct size and recurrent ischemia. However, it is likely that the major impetus for early discharge has been health care reform, specifically the implementation of "critical pathways" and other quality control measures to improve efficiency and reduce the cost of hospital care (20). Although primary PTCA has been advocated as a means of significantly shortening hospital stay, as compared with thrombolytic therapy (21), the differences between length of stay between these two reperfusion modalities in the NRMI experience were rather small.

Hospital mortality declined slightly from 1990 through 1999 in NRMI. The magnitude of mortality decline over time appeared to be somewhat less among those receiving IV thrombolytic therapy, a population generally considered to be at lower risk (22). Among the higher risk, nonthrombolytic recipients, the fall in mortality may have been related to increasing use of appropriate pharmacologic therapy. These hospital mortality data should be interpreted with caution, however. By definition, they do not account for patients after hospital discharge. Furthermore, they do not account for patients transferred from the NRMI hospital to another institution. The trends in hospital mortality may also have been impacted somewhat by the progressively shorter lengths of hospital stay. However, individual mortality trend analyses for each of the first three days of hospital stay showed significant declines from 1990 through 1999. The mortality data may also have been influenced by changing hospital definitions for AMI over time. With the adoption of newer serum markers, such as troponin I or T, a larger proportion of smaller and lower risk infarctions may have been entered into the registry over time.

Study limitations.   The limitations of the NRMI have been enumerated previously (3), and primarily include the fact that 1) registry hospitals, though numerous, may not be representative of all U.S. hospitals; 2) there is no on-site validation of data collection forms; and 3) there is no follow-up after hospital discharge. However, a recent study has shown very close agreement between data collected by NRMI coordinators and data collected independently by chart abstractors for the Cooperative Cardiovascular Project in Medicare-eligible patients at hospitals participating in both studies (23). A limitation unique to the present report is the potential for the trend data to be distorted by the changing hospital composition of the registry. To address this concern, data were examined from core hospitals that consistently contributed to the registry over time. In almost all instances, there was close agreement between the overall registry data and data of the core hospitals. Another potential limitation is the fact that, although medication usage is tracked, NRMI does not attempt to assess clinical eligibility for each medication. Thus, failure to use certain medications may reflect contraindications to their use. However, assuming the characteristics of the population does not change substantially over time, the trend analyses still properly reflect the change in frequency of usage of the medications.

Conclusions.   These data from the NRMI during the period 1990–1999 show that practitioners are initiating thrombolytic therapy faster, using primary PTCA and proven life-saving adjunctive pharmacotherapy more commonly and discharging patients sooner. There appears to be a declining hospital mortality for AMI. It is likely that many of these favorable trends resulted directly from participation in this registry, which provided participating hospitals with quarterly summaries of their individual hospital data, along with that of hospitals of like size and invasive capability.

Despite these favorable trends, it is evident that more work remains to be done. Over 25% of patients presenting within the first 12 h of symptom onset with ST segment elevation or LBBB fail to receive a reperfusion intervention; door-to-drug time remains suboptimal, especially the data-to-decision subinterval; and there is the potential to further expand the use of potentially beneficial pharmacotherapy such as aspirin, beta-blockers and ACE inhibitors. Accordingly, the next phase of the registry (NRMI 4) will place increased emphasis on the identification and treatment of patients eligible for reperfusion, while continuing to emphasize rapid delivery of reperfusion interventions and appropriate use of adjunctive pharmacotherapy.

	Footnotes

 
Support for this research and for The National Registry of Myocardial Infarction was provided by Genentech, Inc.

^¶ A complete listing of participating registry hospitals is available from STATPROBE, Inc., Lexington, Kentucky.

	References

Top Abstract Methods Results Discussion References

 
1. Yusuf S, Sleight P, Held P, McMahon S. Routine medical management of acute myocardial infarction: lessons from overviews of recent randomized controlled trials. Circulation. 1990;82(Suppl II):II117–II134

2. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol. 1996;28:1328–1428[CrossRef][Medline]

3. Participants in the National Registry of Myocardial InfarctionRogers WJ, Bowlby LJ, Chandra NC, et al. Treatment of myocardial infarction in the United States (1990 to 1993): observations from the National Registry of Myocardial Infarction. Circulation. 1994;90:2103–2114[Abstract/Free Full Text]

4. National Heart Attack Alert Program Coordinating Committee 60 Minutes to Treatment Working Group. Emergency department: rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med. 1994;23:311–329[Medline]

5. Gruppo Italiano per lo Studio della Streptochinasa Nell’Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397–402[CrossRef][Medline]

6. TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non–Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation. 1994;89:1545–1556[Abstract/Free Full Text]

7. National Registry of Myocardial Infarction 2 InvestigatorsBarron HV, Bowlby LJ, Breen T, et al. Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation. 1998;97:1150–1156[Abstract/Free Full Text]

8. Second International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349–360[Medline]

9. Second National Registry of Myocardial Infarction (NRMI 2) InvestigatorsAl-Mubarak N, Rogers WJ, Lambrew CT, Bowlby LJ, French WJ. Consultation before thrombolytic therapy in acute myocardial infarction. Am J Cardiol. 1998;83:89–93[CrossRef]

10. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659–675[Free Full Text]

11. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27:335–371[Medline]

12. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction. Circulation. 1998;97:2202–2212[Abstract/Free Full Text]

13. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326–1331[Abstract/Free Full Text]

14. MacMahon S, Collins R, Peto R, Koster RW, Yusuf S. Effects of prophylactic lidocaine in suspected acute myocardial infarction: an overview of results from the randomized, controlled trials. JAMA. 1999;260:1910–1916

15. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716–722[CrossRef][Medline]

16. TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) phase II trial. N Engl J Med. 1989;320:618–627[Abstract]

17. Should We Intervene Following Thrombolysis (SWIFT)? Trial Study Group. SWIFT trial of delayed elective intervention vs. conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ. 1991;302:555–560[Abstract/Free Full Text]

18. Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial InvestigatorsBoden WE, O’Rourke RA, Crawford MH, et al. Outcomes in patients with acute non–Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 1998;338:1785–1792[Abstract/Free Full Text]

19. FRISC II Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708–715[CrossRef][Medline]

20. Pearson SD, Goulart-Fisher D, Lee TH. Critical pathways as a strategy for improving care: problems and potential. Ann Intern Med. 1995;123:941–948[Abstract/Free Full Text]

21. Stone GW, Grines CL, Browne KF, et al. Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty. J Am Coll Cardiol. 1995;26:66–72[Abstract]

22. Cragg DR, Friedman HZ, Bonema JD, et al. Outcome of patients with acute myocardial infarction who are ineligible for thrombolytic therapy. Ann Intern Med. 1991;115:173–177[Abstract/Free Full Text]

23. Every NR, Frederick PD, Robinson M, Sugarman J, Bowlby L, Barron HV. A comparison of the National Registry of Myocardial Infarction 2 with the Cooperative Cardiovascular Project. J Am Coll Cardiol. 1998;33:1886–1894

This article has been cited by other articles:

				V. Vaccarino, L. Parsons, E. D. Peterson, W. J. Rogers, C. I. Kiefe, and J. Canto Sex Differences in Mortality After Acute Myocardial Infarction: Changes From 1994 to 2006 Arch Intern Med, October 26, 2009; 169(19): 1767 - 1774. [Abstract] [Full Text] [PDF]

				Y. B. Pride, J. G. Canto, P. D. Frederick, C. M. Gibson, and for the NRMI Investigators Outcomes Among Patients With Non-ST-Segment Elevation Myocardial Infarction Presenting to Interventional Hospitals With and Without On-Site Cardiac Surgery J. Am. Coll. Cardiol. Intv., October 1, 2009; 2(10): 944 - 952. [Abstract] [Full Text] [PDF]

				C. Berry, K. S. Pieper, H. D. White, S. D. Solomon, F. Van de Werf, E. J. Velazquez, A. P. Maggioni, R. M. Califf, M. A. Pfeffer, and J. J.V. McMurray Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT) Eur. Heart J., June 2, 2009; 30(12): 1450 - 1456. [Abstract] [Full Text] [PDF]

				F. Schiele, N. Meneveau, M. F. Seronde, V. Descotes-Genon, J. Oettinger, F. Ecarnot, J.-P. Bassand, and on behalf of the 'Reseau de Cardiologie de Franche Changes in management of elderly patients with myocardial infarction Eur. Heart J., April 2, 2009; 30(8): 987 - 994. [Abstract] [Full Text] [PDF]

				N. I. Parikh, P. Gona, M. G. Larson, C. S. Fox, E. J. Benjamin, J. M. Murabito, C. J. O'Donnell, R. S. Vasan, and D. Levy Long-Term Trends in Myocardial Infarction Incidence and Case Fatality in the National Heart, Lung, and Blood Institute's Framingham Heart Study Circulation, March 10, 2009; 119(9): 1203 - 1210. [Abstract] [Full Text] [PDF]

				R. Senior Outcome after primary percutaneous intervention in acute myocardial infarction: role of microcirculatory perfusion--a crucial piece in the puzzle Eur. Heart J., March 1, 2009; 30(5): 530 - 531. [Full Text] [PDF]

				K. C. Floyd, J. Yarzebski, F. A. Spencer, D. Lessard, J. E. Dalen, J. S. Alpert, J. M. Gore, and R. J. Goldberg A 30-Year Perspective (1975-2005) Into the Changing Landscape of Patients Hospitalized With Initial Acute Myocardial Infarction: Worcester Heart Attack Study Circ Cardiovasc Qual Outcomes, March 1, 2009; 2(2): 88 - 95. [Abstract] [Full Text] [PDF]

				M. Myerson, S. Coady, H. Taylor, W. D. Rosamond, D. C. Goff Jr, and for the ARIC Investigators Declining Severity of Myocardial Infarction From 1987 to 2002: The Atherosclerosis Risk in Communities (ARIC) Study Circulation, February 3, 2009; 119(4): 503 - 514. [Abstract] [Full Text] [PDF]

				J. G. Robinson, S. Wang, B. J. Smith, and T. A. Jacobson Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 316 - 322. [Abstract] [Full Text] [PDF]

				J. A. Ezekowitz, P. Kaul, J. A. Bakal, P. W. Armstrong, R. C. Welsh, and F. A. McAlister Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J. Am. Coll. Cardiol., January 6, 2009; 53(1): 13 - 20. [Abstract] [Full Text] [PDF]

				L. H. Schwamm, G. C. Fonarow, M. J. Reeves, W. Pan, M. R. Frankel, E. E. Smith, G. Ellrodt, C. P. Cannon, L. Liang, E. Peterson, et al. Get With the Guidelines-Stroke Is Associated With Sustained Improvement in Care for Patients Hospitalized With Acute Stroke or Transient Ischemic Attack Circulation, January 6, 2009; 119(1): 107 - 115. [Abstract] [Full Text] [PDF]

				R. S. Velagaleti, M. J. Pencina, J. M. Murabito, T. J. Wang, N. I. Parikh, R. B. D'Agostino, D. Levy, W. B. Kannel, and R. S. Vasan Long-Term Trends in the Incidence of Heart Failure After Myocardial Infarction Circulation, November 11, 2008; 118(20): 2057 - 2062. [Abstract] [Full Text] [PDF]

				A. S. Adabag, T. M. Therneau, B. J. Gersh, S. A. Weston, and V. L. Roger Sudden Death After Myocardial Infarction JAMA, November 5, 2008; 300(17): 2022 - 2029. [Abstract] [Full Text] [PDF]

				R. H. Mehta, L. Liang, A. M. Karve, A. F. Hernandez, J. S. Rumsfeld, G. C. Fonarow, and E. D. Peterson Association of Patient Case-Mix Adjustment, Hospital Process Performance Rankings, and Eligibility for Financial Incentives JAMA, October 22, 2008; 300(16): 1897 - 1903. [Abstract] [Full Text] [PDF]

				L Wei, C C Lang, F M Sullivan, P Boyle, J Wang, S D Pringle, and T M MacDonald Impact on mortality following first acute myocardial infarction of distance between home and hospital: cohort study Heart, September 1, 2008; 94(9): 1141 - 1146. [Abstract] [Full Text] [PDF]

				G. W. Stone Angioplasty Strategies in ST-Segment-Elevation Myocardial Infarction: Part II: Intervention After Fibrinolytic Therapy, Integrated Treatment Recommendations, and Future Directions Circulation, July 29, 2008; 118(5): 552 - 566. [Full Text] [PDF]

				H. H. Ting, E. H. Bradley, Y. Wang, J. H. Lichtman, B. K. Nallamothu, M. D. Sullivan, B. J. Gersh, V. L. Roger, J. P. Curtis, and H. M. Krumholz Factors Associated With Longer Time From Symptom Onset to Hospital Presentation for Patients With ST-Elevation Myocardial Infarction Arch Intern Med, May 12, 2008; 168(9): 959 - 968. [Abstract] [Full Text] [PDF]

				R Gao, A Patel, W Gao, D Hu, D Huang, L Kong, W Qi, Y Wu, Y Yang, P Harris, et al. Prospective observational study of acute coronary syndromes in China: practice patterns and outcomes Heart, May 1, 2008; 94(5): 554 - 560. [Abstract] [Full Text] [PDF]

				L. H. Curtis, D. J. Whellan, B. G. Hammill, A. F. Hernandez, K. J. Anstrom, A. M. Shea, and K. A. Schulman Incidence and Prevalence of Heart Failure in Elderly Persons, 1994-2003 Arch Intern Med, February 25, 2008; 168(4): 418 - 424. [Abstract] [Full Text] [PDF]

				S. A. Hayat and R. Senior Myocardial contrast echocardiography in ST elevation myocardial infarction: ready for prime time? Eur. Heart J., February 1, 2008; 29(3): 299 - 314. [Abstract] [Full Text] [PDF]

				J. Oldgren, L. Wallentin, R. Afzal, J.-P. Bassand, A. Budaj, S. Chrolavicius, K. A.A. Fox, C. B. Granger, S. R. Mehta, P. Pais, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment Eur. Heart J., February 1, 2008; 29(3): 315 - 323. [Abstract] [Full Text] [PDF]

				R. Vijayaraghavan, A. T. Yan, M. Tan, D. H. Fitchett, A. A. Georgescu, Q. Hassan, A. Langer, S. G. Goodman, and for the Canadian Acute Coronary Syndromes Registry Local hospital vs. core-laboratory interpretation of the admission electrocardiogram in acute coronary syndromes: increased mortality in patients with unrecognized ST-elevation myocardial infarction Eur. Heart J., January 1, 2008; 29(1): 31 - 37. [Abstract] [Full Text] [PDF]

				M. P. Anstadt and J. E. Lowe Cardiopulmonary Resuscitation Card. Surg. Adult, January 1, 2008; 3(2008): 487 - 506. [Full Text]

				J. G. Jollis, M. L. Roettig, A. O. Aluko, K. J. Anstrom, R. J. Applegate, J. D. Babb, P. B. Berger, D. J. Bohle, S. M. Fletcher, J. L. Garvey, et al. Implementation of a Statewide System for Coronary Reperfusion for ST-Segment Elevation Myocardial Infarction JAMA, November 28, 2007; 298(20): 2371 - 2380. [Abstract] [Full Text] [PDF]

				R. J. Goldberg, F. A. Spencer, P. G. Steg, M. Flather, G. Montalescot, E. P. Gurfinkel, B. M. Kennelly, S. G. Goodman, R. Dedrick, J. M. Gore, et al. Increasing Use of Single and Combination Medical Therapy in Patients Hospitalized for Acute Myocardial Infarction in the 21st Century: A Multinational Perspective Arch Intern Med, September 10, 2007; 167(16): 1766 - 1773. [Abstract] [Full Text] [PDF]

				J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF]

				C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Hypertension, August 1, 2007; 50(2): e28 - e55. [Full Text] [PDF]

				X. Zhou, G.-C. Fan, X. Ren, J. R. Waggoner, K. N. Gregory, G. Chen, W. K. Jones, and E. G. Kranias Overexpression of histidine-rich Ca-binding protein protects against ischemia/reperfusion-induced cardiac injury Cardiovasc Res, August 1, 2007; 75(3): 487 - 497. [Abstract] [Full Text] [PDF]

				A. A. Elesber, A. Prasad, R. J. Lennon, R. S. Wright, A. Lerman, and C. S. Rihal Four-Year Recurrence Rate and Prognosis of the Apical Ballooning Syndrome J. Am. Coll. Cardiol., July 31, 2007; 50(5): 448 - 452. [Abstract] [Full Text] [PDF]

				G. Dwivedi, R. Janardhanan, S. A. Hayat, J. M. Swinburn, and R. Senior Prognostic Value of Myocardial Viability Detected by Myocardial Contrast Echocardiography Early After Acute Myocardial Infarction J. Am. Coll. Cardiol., July 24, 2007; 50(4): 327 - 334. [Abstract] [Full Text] [PDF]

				A. K. Jacobs, E. M. Antman, D. P. Faxon, T. Gregory, and P. Solis Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: Executive Summary Circulation, July 10, 2007; 116(2): 217 - 230. [Full Text] [PDF]

				D. P. Faxon Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: Current State of ST-Elevation Myocardial Infarction Care Circulation, July 10, 2007; 116(2): e29 - e32. [Full Text] [PDF]

				P. Moyer, J. P. Ornato, W. J. Brady Jr, L. L. Davis, C. A. Ghaemmaghami, W. B. Gibler, G. Mears, V. N. Mosesso Jr, and R. D. Zane Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: The Emergency Medical Services and Emergency Department Perspective Circulation, July 10, 2007; 116(2): e43 - e48. [Full Text] [PDF]

				E. S. Ford, U. A. Ajani, J. B. Croft, J. A. Critchley, D. R. Labarthe, T. E. Kottke, W. H. Giles, and S. Capewell Explaining the Decrease in U.S. Deaths from Coronary Disease, 1980-2000 N. Engl. J. Med., June 7, 2007; 356(23): 2388 - 2398. [Abstract] [Full Text] [PDF]

				C. Rosendorff, H. R. Black, C. P. Cannon, B. J. Gersh, J. Gore, J. L. Izzo Jr, N. M. Kaplan, C. M. O'Connor, P. T. O'Gara, and S. Oparil Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease: A Scientific Statement From the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention Circulation, May 29, 2007; 115(21): 2761 - 2788. [Full Text] [PDF]

				K. P. Alexander, L. K. Newby, C. P. Cannon, P. W. Armstrong, W. B. Gibler, M. W. Rich, F. Van de Werf, H. D. White, W. D. Weaver, M. D. Naylor, et al. Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology Circulation, May 15, 2007; 115(19): 2549 - 2569. [Abstract] [Full Text] [PDF]

				K. A. A. Fox, P. G. Steg, K. A. Eagle, S. G. Goodman, F. A. Anderson Jr, C. B. Granger, M. D. Flather, A. Budaj, A. Quill, J. M. Gore, et al. Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006 JAMA, May 2, 2007; 297(17): 1892 - 1900. [Abstract] [Full Text] [PDF]

				G. E. Kikano and M. T. Brown Antiplatelet Therapy for Atherothrombotic Disease: An Update for the Primary Care Physician Mayo Clin. Proc., May 1, 2007; 82(5): 583 - 593. [Abstract] [Full Text] [PDF]

				R. J. Gibbons Leading the Elephant Out of the Corner: The Future of Health Care: Presidential Address at the American Heart Association 2006 Scientific Sessions Circulation, April 24, 2007; 115(16): 2221 - 2230. [Full Text] [PDF]

				T. C. Bailey, L. A. Noirot, A. Blickensderfer, E. Rachmiel, R. Schaiff, A. Kessels, A. Braverman, A. Goldberg, B. Waterman, and W. C. Dunagan An Intervention to Improve Secondary Prevention of Coronary Heart Disease Arch Intern Med, March 26, 2007; 167(6): 586 - 590. [Abstract] [Full Text] [PDF]

				C. S. Hollenbeak, J. P. Fitzgibbons, M. Rossi, D. L. Morris, and P. Stillman The Impact of Percutaneous Coronary Interventions on Outcomes for Acute Myocardial Infarction in Pennsylvania American Journal of Medical Quality, March 1, 2007; 22(2): 85 - 94. [Abstract] [PDF]

				H. C. Wijeysundera, R. Vijayaraghavan, B. K. Nallamothu, J. M. Foody, H. M. Krumholz, C. O. Phillips, A. Kashani, J. J. You, J. V. Tu, and D. T. Ko Rescue Angioplasty or Repeat Fibrinolysis After Failed Fibrinolytic Therapy for ST-Segment Myocardial Infarction: A Meta-Analysis of Randomized Trials J. Am. Coll. Cardiol., January 30, 2007; 49(4): 422 - 430. [Abstract] [Full Text] [PDF]

				E. C. Keeley and L. D. Hillis Primary PCI for Myocardial Infarction with ST-Segment Elevation N. Engl. J. Med., January 4, 2007; 356(1): 47 - 54. [Full Text] [PDF]

				A. B. Rosen, D. M. Cutler, D. M. Norton, H. M. Hu, and S. Vijan The Value Of Coronary Heart Disease Care For The Elderly: 1987-2002 Health Aff., January 1, 2007; 26(1): 111 - 123. [Abstract] [Full Text] [PDF]

				F. A. Masoudi, J. M. Foody, E. P. Havranek, Y. Wang, M. J. Radford, R. M. Allman, J. Gold, R. T. Wiblin, and H. M. Krumholz Trends in Acute Myocardial Infarction in 4 US States Between 1992 and 2001: Clinical Characteristics, Quality of Care, and Outcomes Circulation, December 19, 2006; 114(25): 2806 - 2814. [Abstract] [Full Text] [PDF]

				H. H. Ting, E. H. Yang, and C. S. Rihal Narrative review: reperfusion strategies for ST-segment elevation myocardial infarction. Ann Intern Med, October 17, 2006; 145(8): 610 - 617. [Abstract] [Full Text] [PDF]

				R. H. Mehta, M. T. Roe, A. Y. Chen, B. L. Lytle, C. V. Pollack Jr, R. G. Brindis, S. C. Smith Jr, R. A. Harrington, D. Fintel, E. S. Fraulo, et al. Recent Trends in the Care of Patients With Non-ST-Segment Elevation Acute Coronary Syndromes: Insights From the CRUSADE Initiative. Arch Intern Med, October 9, 2006; 166(18): 2027 - 2034. [Abstract] [Full Text] [PDF]

				P. M. Ho, J. A. Spertus, F. A. Masoudi, K. J. Reid, E. D. Peterson, D. J. Magid, H. M. Krumholz, and J. S. Rumsfeld Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med, September 25, 2006; 166(17): 1842 - 1847. [Abstract] [Full Text] [PDF]

				A. Schomig, G. Ndrepepa, and A. Kastrati Late myocardial salvage: time to recognize its reality in the reperfusion therapy of acute myocardial infarction Eur. Heart J., August 2, 2006; 27(16): 1900 - 1907. [Abstract] [Full Text] [PDF]

				A Oudot, P G Steg, N Danchin, G Dentan, M Zeller, P Sicard, P Buffet, Y Laurent, L Janin-Manificat, I L'Huillier, et al. Impact of chronic oral anticoagulation on management and outcomes of patients with acute myocardial infarction: data from the RICO survey Heart, August 1, 2006; 92(8): 1077 - 1083. [Abstract] [Full Text] [PDF]

				C. Maynard, E. Lowy, J. Rumsfeld, A. E. Sales, H. Sun, B. Kopjar, B. Fleming, R. L. Jesse, R. Rusch, and S. D. Fihn The prevalence and outcomes of in-hospital acute myocardial infarction in the department of veterans affairs health system. Arch Intern Med, July 10, 2006; 166(13): 1410 - 1416. [Abstract] [Full Text] [PDF]

				D. A. Alter, D. T. Ko, A. Newman, and J. V. Tu Factors explaining the under-use of reperfusion therapy among ideal patients with ST-segment elevation myocardial infarction Eur. Heart J., July 1, 2006; 27(13): 1539 - 1549. [Abstract] [Full Text] [PDF]

				Y. Gerber, S. J. Jacobsen, R. L. Frye, S. A. Weston, J. M. Killian, and V. L. Roger Secular Trends in Deaths From Cardiovascular Diseases: A 25-Year Community Study Circulation, May 16, 2006; 113(19): 2285 - 2292. [Abstract] [Full Text] [PDF]

				E. Bjorklund, U. Stenestrand, J. Lindback, L. Svensson, L. Wallentin, B. Lindahl, and on behalf of the RIKS-HIA Investigators Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction Eur. Heart J., May 2, 2006; 27(10): 1146 - 1152. [Abstract] [Full Text] [PDF]

				E. W. Tang, C.-K. Wong, N. J. Restieaux, P. Herbison, M. J. A. Williams, P. Kay, and G. T. Wilkins Clinical outcome of older patients with acute coronary syndrome over the last three decades. Age Ageing, May 1, 2006; 35(3): 280 - 285. [Abstract] [Full Text] [PDF]

				S. D. Wiviott, D. A. Morrow, P. D. Frederick, E. M. Antman, and E. Braunwald Application of the Thrombolysis In Myocardial Infarction Risk Index in Non-ST-Segment Elevation Myocardial Infarction: Evaluation of Patients in the National Registry of Myocardial Infarction J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1553 - 1558. [Abstract] [Full Text] [PDF]

				B. J. Gersh and E. M. Antman Selection of the optimal reperfusion strategy for STEMI: does time matter? Eur. Heart J., April 1, 2006; 27(7): 761 - 763. [Full Text] [PDF]

				R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Circulation, March 14, 2006; 113(10): e409 - e449. [Abstract] [Full Text] [PDF]

				T. Thom, N. Haase, W. Rosamond, V. J. Howard, J. Rumsfeld, T. Manolio, Z.-J. Zheng, K. Flegal, C. O'Donnell, S. Kittner, et al. Heart Disease and Stroke Statistics--2006 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation, February 14, 2006; 113(6): e85 - e151. [Full Text] [PDF]

				J. L. Garvey, B. A. MacLeod, G. Sopko, M. M. Hand, and on behalf of the National Heart Attack Alert Progr Pre-Hospital 12-Lead Electrocardiography Programs: A Call for Implementation by Emergency Medical Services Systems Providing Advanced Life Support--National Heart Attack Alert Program (NHAAP) Coordinating Committee; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health J. Am. Coll. Cardiol., February 7, 2006; 47(3): 485 - 491. [Abstract] [Full Text] [PDF]

				R. L. Sacco, R. Adams, G. Albers, M. J. Alberts, O. Benavente, K. Furie, L. B. Goldstein, P. Gorelick, J. Halperin, R. Harbaugh, et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke: Co-Sponsored by the Council on Cardiovascular Radiology and Intervention: The American Academy of Neurology affirms the value of this guideline. Stroke, February 1, 2006; 37(2): 577 - 617. [Abstract] [Full Text] [PDF]

				L. K. Newby, N. M. Allen LaPointe, A. Y. Chen, J. M. Kramer, B. G. Hammill, E. R. DeLong, L. H. Muhlbaier, and R. M. Califf Long-Term Adherence to Evidence-Based Secondary Prevention Therapies in Coronary Artery Disease Circulation, January 17, 2006; 113(2): 203 - 212. [Abstract] [Full Text] [PDF]

				B. K. Nallamothu, Y. Wang, D. J. Magid, R. L. McNamara, J. Herrin, E. H. Bradley, E. R. Bates, C. V. Pollack Jr, H. M. Krumholz, and for the National Registry of Myocardial Infarction Relation Between Hospital Specialization With Primary Percutaneous Coronary Intervention and Clinical Outcomes in ST-Segment Elevation Myocardial Infarction: National Registry of Myocardial Infarction-4 Analysis Circulation, January 17, 2006; 113(2): 222 - 229. [Abstract] [Full Text] [PDF]

				R. L. McNamara, J. Herrin, E. H. Bradley, E. L. Portnay, J. P. Curtis, Y. Wang, D. J. Magid, M. Blaney, H. M. Krumholz, and for the NRMI Investigators Hospital Improvement in Time to Reperfusion in Patients With Acute Myocardial Infarction, 1999 to 2002 J. Am. Coll. Cardiol., January 3, 2006; 47(1): 45 - 51. [Abstract] [Full Text] [PDF]

				J. W. Eikelboom, D. J. Quinlan, S. R. Mehta, A. G. Turpie, I. B. Menown, and S. Yusuf Unfractionated and Low-Molecular-Weight Heparin as Adjuncts to Thrombolysis in Aspirin-Treated Patients With ST-Elevation Acute Myocardial Infarction: A Meta-Analysis of the Randomized Trials Circulation, December 20, 2005; 112(25): 3855 - 3867. [Abstract] [Full Text] [PDF]

				C. Patrono, L. A. Garcia Rodriguez, R. Landolfi, and C. Baigent Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med., December 1, 2005; 353(22): 2373 - 2383. [Full Text] [PDF]

				T. P. Wharton Jr, E. C. Keeley, C. L. Grines, T. P. Wharton Jr, E. C. Keeley, and C. L. Grines The Case for Community Hospital Angioplasty Circulation, November 29, 2005; 112(22): 3509 - 3534. [Full Text] [PDF]

				J. G. Robinson, B. Smith, N. Maheshwari, and H. Schrott Pleiotropic Effects of Statins: Benefit Beyond Cholesterol Reduction?: A Meta-Regression Analysis J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1855 - 1862. [Abstract] [Full Text] [PDF]

				R C Welsh, W Chang, P Goldstein, J Adgey, C B Granger, F W A Verheugt, L Wallentin, F Van de Werf, P W Armstrong, and on behalf of the ASSENT-3 PLUS Investigators Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial Heart, November 1, 2005; 91(11): 1400 - 1406. [Abstract] [Full Text] [PDF]

				W. A. Jaber, R. J. Lennon, V. Mathew, D. R. Holmes Jr, A. Lerman, and C. S. Rihal Application of Evidence-Based Medical Therapy Is Associated With Improved Outcomes After Percutaneous Coronary Intervention and Is a Valid Quality Indicator J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1473 - 1478. [Abstract] [Full Text] [PDF]

				K. A. Eagle, C. K. Montoye, A. L. Riba, A. C. DeFranco, R. Parrish, S. Skorcz, P. L. Baker, J. Faul, S. M. Jani, B. Chen, et al. Guideline-Based Standardized Care Is Associated With Substantially Lower Mortality in Medicare Patients With Acute Myocardial Infarction: The American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1242 - 1248. [Abstract] [Full Text] [PDF]

				T. J. Meine, M. R. Patel, V. DePuy, L. H. Curtis, S. V. Rao, B. J. Gersh, K. A. Schulman, and J. G. Jollis Evidence-Based Therapies and Mortality in Patients Hospitalized in December with Acute Myocardial Infarction Ann Intern Med, October 4, 2005; 143(7): 481 - 485. [Abstract] [Full Text] [PDF]

				R. Aazami Initial Appraisal of Acute Coronary Syndromes Journal of Pharmacy Practice, October 1, 2005; 18(5): 377 - 393. [Abstract] [PDF]

				D. J. Moliterno and S. R. Steinhubl Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both? JAMA, September 14, 2005; 294(10): 1271 - 1273. [Full Text] [PDF]

				V. Vaccarino, S. S. Rathore, N. K. Wenger, P. D. Frederick, J. L. Abramson, H. V. Barron, A. Manhapra, S. Mallik, H. M. Krumholz, and the National Registry of Myocardial Infarction Inv Sex and Racial Differences in the Management of Acute Myocardial Infarction, 1994 through 2002 N. Engl. J. Med., August 18, 2005; 353(7): 671 - 682. [Abstract] [Full Text] [PDF]

				A. Babaev, P. D. Frederick, D. J. Pasta, N. Every, T. Sichrovsky, J. S. Hochman, and for the NRMI Investigators Trends in Management and Outcomes of Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock JAMA, July 27, 2005; 294(4): 448 - 454. [Abstract] [Full Text] [PDF]

				M. T. Roe, L. S. Parsons, C. V. Pollack Jr, J. G. Canto, H. V. Barron, N. R. Every, W. J. Rogers, E. D. Peterson, and for the National Registry of Myocardial Infarction Quality of Care by Classification of Myocardial Infarction: Treatment Patterns for ST-Segment Elevation vs Non-ST-Segment Elevation Myocardial Infarction Arch Intern Med, July 25, 2005; 165(14): 1630 - 1636. [Abstract] [Full Text] [PDF]

				E. M. Ohman and P. P. Chang Improving Quality of Life After Cardiogenic Shock: Do More Revascularization! J. Am. Coll. Cardiol., July 19, 2005; 46(2): 274 - 276. [Full Text] [PDF]

				A-A Fassa, P Urban, D Radovanovic, N Duvoisin, J-M Gaspoz, J-C Stauffer, P Erne, and for the AMIS Plus Investigators Trends in reperfusion therapy of ST segment elevation myocardial infarction in Switzerland: six year results from a nationwide registry Heart, July 1, 2005; 91(7): 882 - 888. [Abstract] [Full Text] [PDF]

				A. Schomig, J. Mehilli, D. Antoniucci, G. Ndrepepa, C. Markwardt, F. Di Pede, S. G. Nekolla, K. Schlotterbeck, H. Schuhlen, J. Pache, et al. Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting More Than 12 Hours From Symptom Onset: A Randomized Controlled Trial JAMA, June 15, 2005; 293(23): 2865 - 2872. [Abstract] [Full Text] [PDF]

				B. J. Gersh, G. W. Stone, H. D. White, and D. R. Holmes Jr Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Is the Slope of the Curve the Shape of the Future? JAMA, February 23, 2005; 293(8): 979 - 986. [Abstract] [Full Text] [PDF]

				B. K. Nallamothu, E. R. Bates, J. Herrin, Y. Wang, E. H. Bradley, H. M. Krumholz, and for the NRMI Investigators Times to Treatment in Transfer Patients Undergoing Primary Percutaneous Coronary Intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 Analysis Circulation, February 15, 2005; 111(6): 761 - 767. [Abstract] [Full Text] [PDF]

				N. Valeur, P. Clemmensen, K. Saunamaki, P. Grande, and for the DANAMI-2 investigators The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study Eur. Heart J., January 2, 2005; 26(2): 119 - 127. [Abstract] [Full Text] [PDF]

				C. J. Terkelsen, J. F. Lassen, B. L. Norgaard, J. C. Gerdes, T. Jensen, L. B.-H. Gotzsche, T. T. Nielsen, and H. R. Andersen Mortality rates in patients with ST-elevation vs. non-ST-elevation acute myocardial infarction: observations from an unselected cohort Eur. Heart J., January 1, 2005; 26(1): 18 - 26. [Abstract] [Full Text] [PDF]

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rogers, W. J. Search for Related Content PubMed PubMed Citation Articles by Rogers, W. J.